Biological Predictive Factors of Response to ESA in Low Risk MDS Patients
Status:
Completed
Trial end date:
2018-05-01
Target enrollment:
Participant gender:
Summary
In this trial, the investigators would like to understand why a small percentage of patients
will be refractory to ESA (independently of International prognostic scoring system (IPSS)
and % of blasts). In a retrospective study of the "Groupe Francophone des Myélodysplasies
(GFM)" , the investigators showed that about 43% of patients are refractory or will relapse
after initial response to ESA and it has been shown that these patients have a poorer
survival. The investigators plan to give a 12-week treatment of Epoetin alfa or zeta in low
risk MDS patients and measure different biological factors to predict response to ESA:
- evaluation by flow cytometry before and after treatment of the degree of
dyserythropoiesis and dysgranulopoiesis which could explain the primary resistance or
loss of response of a subset of patients,
- screening by molecular biology of predictive factors of response to ESA,
- Iron homeostasis will be measured via hepcidin, GDF-15 and ferritin levels.
Phase:
Phase 4
Details
Lead Sponsor:
Association pour la recherche sur les Affections Malignes en Immunologie Sanguine